Fundraising FoxInkef — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.
BiotechDeep TechMedical DevicesCopenhagen, DK
Simon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)
Co-investorsGilde HealthcareMC Healthcare VenturesNovo Holdings
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investors3B Future Health FundM VenturesVI PartnersXGEN VentureJohnson & Johnson Innovation – JJDC
Belgian cash forecasting and working capital analytics software provider, acquired by Treasury Intelligence Solutions in 2022.
FintechAntwerpen, BE
Co-investorsTechstarsCiti VenturesPamica NVVolta Ventures
Dialectic combines machine intelligence with crypto-native financial tools to build automated financial compounding systems.
AI & Machine LearningCrypto & Web3Fintech
Ryan Zurrer(Founder)in
Co-investorsMarin Digital Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Provable Markets
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.